Clinical Trial Update: Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation [Phase 1]

View source ↗

Summary

This Phase 1 trial update discusses orally administered AG-120 (ivosidenib) for IDH1-mutated hematologic malignancies, including relapsed/refractory AML and unt…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• AG-120 (ivosidenib) (ivosidenib)

Snippet

Sponsor: Institut de Recherches Internationales Servier | Conditions: Relapsed or Refractory Acute Myeloid Leukemia (AML), Untreated AML | Phase 1 | Status: RECRUITING